New Strong Sell Stocks for August 14th
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
Zacks Investment Research8/14/2026Negative
AMPH
Amphastar PNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$889.47M
P/E Ratio
12.37
EPS
$1.69
Beta
0.90
52W High
$31.26
52W Low
$16.64
50-Day MA
$19.83
200-Day MA
$22.77
Dividend Yield
—
Profit Margin
10.80%
Forward P/E
—
PEG Ratio
2.77
About Amphastar P
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Fundamentals
| Revenue (TTM) | $730.02M |
| Gross Profit (TTM) | $348.11M |
| EBITDA | $194.51M |
| Operating Margin | 21.60% |
| Return on Equity | 10.30% |
| Return on Assets | 5.11% |
| Revenue/Share (TTM) | $16.10 |
| Book Value | $18.06 |
| Price-to-Book | 1.16 |
| Price-to-Sales (TTM) | 1.22 |
| EV/Revenue | 1.766 |
| EV/EBITDA | 6.68 |
| Quarterly Earnings Growth (YoY) | 4.70% |
| Quarterly Revenue Growth (YoY) | 5.40% |
| Shares Outstanding | $42.54M |
| Float | $31.28M |
| % Insiders | 30.82% |
| % Institutions | 69.93% |
Historical Volatility
HV 10-Day
39.55%
HV 20-Day
37.37%
HV 30-Day
39.97%
HV 60-Day
43.53%
HV Rank
33.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($22.00 target)
6
Hold1
Strong SellLatest News
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
PRNewsWire8/6/2026Neutral
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/30/2026Negative
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
PRNewsWire7/29/2026Neutral
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.
CNBC7/22/2026Neutral
New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Zacks Investment Research6/23/2026Negative
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.
MarketBeat6/4/2026Positive
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
Accesswire5/27/2026Neutral
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
MarketBeat5/14/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AMPH and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026